1-9 of 9
Tomas Radivoyevitch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer

Treg Grubb, Smruthi Maganti, John Michael Krill-Burger, Cameron Fraser, Laura Stransky, Tomas Radivoyevitch, Kristopher A. Sarosiek, Francisca Vazquez, William G. Kaelin, Jr, Abhishek A. Chakraborty
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4689–4701.
https://doi.org/10.1158/1078-0432.CCR-22-0669
Published: 01 November 2022
View article titled, A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-X<sub>L</sub> Antiapoptotic Protein in Kidney Cancer
Open the PDF for A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-X<sub>L</sub> Antiapoptotic Protein in Kidney Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome

Balint Otvos, Tyler J. Alban, Matthew M. Grabowski, Defne Bayik, Erin E. Mulkearns-Hubert, Tomas Radivoyevitch, Anja Rabljenovic, Sarah Johnson, Charlie Androjna, Alireza M. Mohammadi, Gene H. Barnett, Manmeet S. Ahluwalia, Michael A. Vogelbaum, Peter E. Fecci, Justin D. Lathia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 2038–2049.
https://doi.org/10.1158/1078-0432.CCR-20-3262
Published: 01 April 2021
View article titled, Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome
Open the PDF for Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome in another window
Includes: Supplementary data
Journal Articles

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

Remco J. Molenaar, Tomas Radivoyevitch, Yasunobu Nagata, Mohammed Khurshed, Bartolomiej Przychodzen, Hideki Makishima, Mingjiang Xu, Fonnet E. Bleeker, Johanna W. Wilmink, Hetty E. Carraway, Sudipto Mukherjee, Mikkael A. Sekeres, Cornelis J.F. van Noorden, Jaroslaw P. Maciejewski
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (7): 1705–1715.
https://doi.org/10.1158/1078-0432.CCR-17-2796
Published: 02 April 2018
View article titled, <em>IDH1/2</em> Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Open the PDF for <em>IDH1/2</em> Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors in another window
Includes: Supplementary data
Journal Articles

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarroki, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelke, Mikkael A. Sekeres, Ramon Tiu, Jaroslaw Maciejewski, Tomas Radivoyevitch, Yogen Saunthararajah
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 938–948.
https://doi.org/10.1158/1078-0432.CCR-12-1722
Published: 14 February 2013
View article titled, Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Open the PDF for Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy in another window
Includes: Supplementary data
Journal Articles

Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

Beth Overmoyer, Pingfu Fu, Charles Hoppel, Tomas Radivoyevitch, Robert Shenk, Marjie Persons, Paula Silverman, Kelly Robertson, Nicholas P. Ziats, Jay K. Wasman, Fadi W. Abdul-Karim, John A. Jesberger, Jeffrey Duerk, Paul Hartman, Shelli Hanks, Jonathan Lewin, Afshin Dowlati, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5862–5868.
https://doi.org/10.1158/1078-0432.CCR-07-0688
Published: 01 October 2007
View article titled, Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin
Open the PDF for Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin in another window
Journal Articles

Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416

Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, John Waas, Nicholas P. Ziats, Paul Hartman, Fadi W. Abdul-Karim, Jay K. Wasman, Jack Jesberger, Jonathan Lewin, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7938–7944.
https://doi.org/10.1158/1078-0432.CCR-04-2538
Published: 08 November 2005
View article titled, Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416
Open the PDF for Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 in another window
Journal Articles

Schedule-Dependent Drug Effects of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose as an In vivo Radiosensitizer in U251 Human Glioblastoma Xenografts

Yuji Seo, Tao Yan, Jane E. Schupp, Tomas Radivoyevitch, Timothy J. Kinsella
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (20): 7499–7507.
https://doi.org/10.1158/1078-0432.CCR-05-1138
Published: 20 October 2005
View article titled, Schedule-Dependent Drug Effects of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose as an <em>In vivo</em> Radiosensitizer in U251 Human Glioblastoma Xenografts
Open the PDF for Schedule-Dependent Drug Effects of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose as an <em>In vivo</em> Radiosensitizer in U251 Human Glioblastoma Xenografts in another window
Journal Articles

A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia

Brenda W. Cooper, Gareth J. Veal, Tomas Radivoyevitch, Michael J. Tilby, Howard J. Meyerson, Hillard M. Lazarus, Omer N. Koc, Richard J. Creger, Graham Pearson, Geoff M. Nowell, David Gosky, Stephen T. Ingalls, Charles L. Hoppel, Stanton L. Gerson
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (20): 6830–6839.
https://doi.org/10.1158/1078-0432.CCR-04-0097
Published: 22 October 2004
View article titled, A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia
Open the PDF for A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia in another window
Journal Articles

Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

Matthew M. Cooney, Tomas Radivoyevitch, Afshin Dowlati, Beth Overmoyer, Nathan Levitan, Kelly Robertson, Sandra L. Levine, Kathleen DeCaro, Carol Buchter, Anne Taylor, Bruce S. Stambler, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 96–100.
https://doi.org/10.1158/1078-0432.CCR-0364-3
Published: 20 January 2004
View article titled, Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer
Open the PDF for Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer in another window